INVIMA FIH Device Classification in Colombia: Decree 4725 Rules That Decide the Protocol Path

Most INVIMA first-in-human (FIH) delays I see do not start on the Sala Especializada calendar. They start when regulatory affairs copies a U.S. Class II 510(k) letter into the Colombian file and calls it a classification. Decree 4725 of 2005 does not work that way. The manufacturer classifies the device from intended purpose, duration of body contact, invasiveness, and local versus systemic effect, using the Article 7 rules. The most stringent applicable rule wins. If that call is wrong, the technical concept you are waiting for is the wrong concept.

This is not the INVIMA sanitary-registration checklist. Registro sanitario / permiso de comercialización is a different operating system — uncontrolled Class I/IIa automatic registration versus controlled IIb/III review, legal representative, CCAA importer, UDI-DI under Resolution 1405 of 2022. This article is the classification decision that decides how an investigational, often unregistered, device enters a human protocol in Colombia.

What INVIMA means by an investigational device

Decree 4725 Article 2 defines a “dispositivo médico destinado a investigaciones clínicas” as any medical device to be used by a specialist physician in investigations carried out in an adequate human clinical setting. The same article defines a clinical study as any investigation in human beings intended to discover or verify clinical or other effects of medical devices and/or to identify any adverse reaction, in order to confirm safety and/or effectiveness. A “equipo biomédico prototipo” is equipment still in an experimental phase that has not been used in care or demonstration and that lacks a free-sale certificate from the competent authority in the country of origin.

Article 36 then draws a hard line sponsors blur: a prototype device or controlled-technology biomedical equipment, national or imported, may be authorized only for research and experimentation and may not be used in health care. Import of such prototypes requires an INVIMA technical concept, in accordance with the health-research rules in force. Article 48(b) is the complementary import valve: INVIMA may exceptionally authorize import of a finished device without a sanitary registration when the Ministry or INVIMA has authorized clinical investigation in the country, after the competent specialized room has issued its concept. Article 55(n) requires labeling to state that the device is specifically for clinical and/or performance investigations before market launch. If your cartons look like a commercial shipment, you have already broken the classification story.

In vitro diagnostics are carved out of Decree 4725 (Article 1, paragraph 1) and sit on Decree 3770 of 2004. Do not force an IVD performance study into the implant classification box. INVIMA’s device clinical-investigation page publishes separate IVD forms (ASS-RSA-FM082, FM083) for that reason.

The four classes that actually drive the FIH file

Article 5 of Decree 4725 is the class rule:

• Class I — low risk, general controls; not intended to protect or sustain life or for a special use in preventing deterioration of health; no unreasonable potential risk of illness or injury.
• Class IIa — moderate risk, special manufacturing controls to demonstrate safety and effectiveness.
• Class IIb — high risk, special design and manufacturing controls to demonstrate safety and effectiveness.
• Class III — very high risk, special controls; intended to protect or sustain life or for a substantial use in preventing deterioration of health, or presenting a potential risk of illness or injury.

Article 6 says the rules follow intended purpose. Accessories are classified on their own intended purpose when used with another device. Software that drives or influences a device inherits that device’s class. If the device is not intended mainly for one body site, classify on the most critical specified use. If several rules apply, take the highest class.

Article 7 is where FIH programs actually break. The rules that recur on first-in-human device boards:

• Rule 6 / 7 — surgically invasive devices. Transient surgical tools default IIa (reusable instruments can be I). Direct contact with the heart or central circulatory system to diagnose, monitor or correct a defect is Class III even for short use. Direct contact with the central nervous system is Class III for short-term surgical invasives (Rule 7).
• Rule 8 — implants and long-term surgically invasive devices default IIb, and jump to Class III if they contact heart, central circulation or CNS, exert a biological effect or are largely absorbed, or undergo chemical change in the body / administer a medicinal product (teeth placements excepted).
• Rule 9–11 — active therapeutic and diagnostic devices, and devices that administer or withdraw substances. “Potentially hazardous” energy or delivery is IIb, not IIa.
• Rule 13 — a device that incorporates, as an integral part, a substance that would be a medicine if used separately, and that substance has an action ancillary to the device, is Class III.
• Rule 17 — devices manufactured using non-viable animal tissues or derivatives are Class III unless they contact intact skin only.

A U.S. “non-significant-risk” or 510(k) Class II label is not a Colombian class. A coronary-contact catheter that someone files as IIa because “it is only diagnostic” is still Rule 6(e) / 7(c) territory if the intended purpose is direct contact with the central circulation. Write the Spanish intended-purpose sentence first. Then apply the rule. Then name the class. If clinical, quality, and the Colombian legal representative cannot repeat those three lines, you are not ready to talk to a Comité de Ética en Investigación (CEI).

How class changes the investigation path — not the registration path

INVIMA’s Dirección de Dispositivos Médicos y Otras Tecnologías runs device clinical investigation through GICASE (Grupo de Investigación Clínica y Apoyo a Sala Especializada), reorganized under INVIMA Resolution 2022035262 of 20 September 2022. The Agency’s public clinical-investigation page is the index of live forms. For a prototype / unregistered device protocol, the checklist that actually opens the technical-concept request is ASS-RSA-FM085. The specialized-room request form is ASS-RSA-FM172. The CEI is expected to complete ASS-RSA-FM169 on initial evaluation of a device (or other-technology) clinical study. After authorization, serious adverse events go on ASS-RSA-FM171 and periodic study reports on ASS-RSA-FM170.

That form set is how class becomes operational. A Class III implant FIH is a prototype investigation: Article 36 technical concept, CEI approval under Resolución 8430 de 1993, and an import path that cites the investigation authorization rather than a DM sanitary-registration number. A Class I/IIa tool that is already registered in Colombia for the same intended purpose is a different conversation — you may still need ethics and institutional authorization under 8430, but you are not pretending the unit is a prototype. A registered device studied for a new intended purpose is a new classification exercise, because Article 6 follows the purpose you will actually use in the protocol, not the purpose on last year’s registro.

Resolución 8430 de 1993 remains the cross-cutting human-research rule INVIMA cites on that same page. Article 6 requires prior laboratory or animal justification, written informed consent, qualified investigators, and authorization from the legal representative of the researching institution, the institution where the work is done, and the institutional research-ethics committee. Article 11 classifies research by risk to the subject. An FIH implant is not “minimal risk.” Do not file it as if it were.

Resolución 2378 de 2008 adopts Good Clinical Practice and BPC certification for institutions that conduct drug research. INVIMA’s device page cites it as part of the national research furniture. It is not the device-classification statute and it is not a substitute for FM085. If your chosen hospital’s only certificate is a medicines BPC, ask GICASE and the CEI what they will accept for a device protocol. Do not invent a waiver in a slide.

What the technical file must prove for the class you claimed

Decree 4725’s commercial dossier rules are still the evidence language reviewers know. Article 18(j)–(k) is the tell: IIa/IIb/III need scientific information supporting safety and a risk analysis; IIb and III need clinical studies on use to demonstrate safety and effectiveness — for a marketed file. For an FIH, you do not yet have those clinical studies. What you must have is the nonclinical justification 8430 Article 6 demands, a risk-management file that matches the Article 7 rule you applied, biocompatibility and bench data for the tissues and duration you claimed, and an investigator brochure whose “expected” harms match the class. If you classified the device IIb under Rule 8 (implant) and the brochure reads like a Class IIa surgical tool, the specialized room will not fix that with a courtesy question. They will stop the concept.

ISO 14155 is the device GCP you should run to, especially if the same dataset must later support FDA review of foreign data under 21 CFR 812.28. Decree 4725 does not cite ISO 14155 by name. That is not permission to run an FIH without device accountability, investigational labeling (Article 55(n)), or source documents an inspector can reconstruct.

Import is a classification problem. Article 36 plus Article 48(b) are how unregistered units enter. Quantities should match the protocol. The importer still needs a lawful storage/conditioning posture — commercially, that is the CCAA world of Articles 10–11. Do not park investigational implants in a spare bedroom because “it is not a registro shipment.”

Eight lines to lock before CEI submission

1. Intended purpose in Spanish. The sentence that will appear on FM085, the protocol, the brochure, and later — if you commercialize — on the registro. Changing “long-term implant” to “intraoperative aid” after CEI approval is a new class.
2. Article 7 rule and Class I / IIa / IIb / III. Record why neighboring rules were rejected. Heart, central circulation, CNS, animal tissue, and ancillary drug substance are the usual missed upgrades.
3. Prototype versus registered-same-indication versus new-indication-on-a-registered-device. Article 36 applies to prototypes. A new purpose on an old number is not a shortcut.
4. IVD or device. Decree 3770 versus 4725. Wrong form family wastes a Sala cycle.
5. CEI path under 8430. Institutional authorization plus FM169. Name the committee that will actually meet.
6. Technical-concept pack. FM085 + FM172, complete, in the language INVIMA will review. English-only annexes are not a strategy.
7. Import list. Every SKU, spare, and accessory that will move under Article 36 / 48(b), labeled per Article 55(n).
8. Safety reporting owners. FM171 for serious events, FM170 for periodic reports. Expectedness language lives in the brochure you classified against.

This week, run a 90-minute huddle with RA, clinical, quality, and the Colombian legal representative. Put the intended-purpose sentence, the Article 7 rule, the class, and a prototype-versus-registered decision on one page. Attach Decree 4725 Articles 2, 5–7, 36 and 48(b), Resolución 8430 Articles 6 and 11, and the current GICASE form list. If those four people cannot sign the page, do not book first-patient week. The calendar you save is not INVIMA’s. It is the quarter you would have spent unscrewing a class you never locked.